DE602004008874D1 - Rekombinante Proteine, die Epitope des humanen Papillomavirus inseriert in einem Adenylatecyclase Protein oder in dessen Fragmenten tragen, und deren terapeutischen Verwendung. - Google Patents
Rekombinante Proteine, die Epitope des humanen Papillomavirus inseriert in einem Adenylatecyclase Protein oder in dessen Fragmenten tragen, und deren terapeutischen Verwendung.Info
- Publication number
- DE602004008874D1 DE602004008874D1 DE602004008874T DE602004008874T DE602004008874D1 DE 602004008874 D1 DE602004008874 D1 DE 602004008874D1 DE 602004008874 T DE602004008874 T DE 602004008874T DE 602004008874 T DE602004008874 T DE 602004008874T DE 602004008874 D1 DE602004008874 D1 DE 602004008874D1
- Authority
- DE
- Germany
- Prior art keywords
- adenylate cyclase
- fragments
- protein
- recombinant proteins
- therapeutic use
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title abstract 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title abstract 3
- 102000030621 adenylate cyclase Human genes 0.000 title abstract 3
- 108060000200 adenylate cyclase Proteins 0.000 title abstract 3
- 239000012634 fragment Substances 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 241000701806 Human papillomavirus Species 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 abstract 1
- 208000009608 Papillomavirus Infections Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04290741A EP1576967B1 (de) | 2004-03-18 | 2004-03-18 | Rekombinante Proteine, die Epitope des humanen Papillomavirus inseriert in einem Adenylatecyclase Protein oder in dessen Fragmenten tragen, und deren terapeutischen Verwendung. |
Publications (2)
Publication Number | Publication Date |
---|---|
DE602004008874D1 true DE602004008874D1 (de) | 2007-10-25 |
DE602004008874T2 DE602004008874T2 (de) | 2008-06-12 |
Family
ID=34833798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004008874T Expired - Lifetime DE602004008874T2 (de) | 2004-03-18 | 2004-03-18 | Rekombinante Proteine, die Epitope des humanen Papillomavirus inseriert in einem Adenylatecyclase Protein oder in dessen Fragmenten tragen, und deren terapeutischen Verwendung. |
Country Status (19)
Country | Link |
---|---|
US (3) | US8628779B2 (de) |
EP (3) | EP1576967B1 (de) |
JP (2) | JP5438897B2 (de) |
KR (2) | KR101495740B1 (de) |
CN (1) | CN1956730B (de) |
AT (1) | ATE372784T1 (de) |
AU (1) | AU2005224036B2 (de) |
BR (1) | BRPI0508722A (de) |
CA (1) | CA2559235C (de) |
CY (1) | CY1107042T1 (de) |
DE (1) | DE602004008874T2 (de) |
DK (1) | DK1576967T3 (de) |
ES (1) | ES2293178T3 (de) |
MX (1) | MXPA06010469A (de) |
PL (1) | PL1576967T3 (de) |
PT (1) | PT1576967E (de) |
RU (1) | RU2441022C2 (de) |
SI (1) | SI1576967T1 (de) |
WO (1) | WO2005089792A1 (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2331348T3 (es) | 2000-09-15 | 2009-12-30 | Pasteur Institut | Vectores proteinicos para el suministro de moleculas a las celulas que expresan cd11b. |
SI1576967T1 (sl) | 2004-03-18 | 2008-02-29 | Pasteur Institut | Rekombinantni protein, ki nosi epitope humanega papilomavirusa, vstavljene v adenilat ciklazni protein ali njegov fragment, in njegove terapevtske uporabe |
DK2656841T3 (en) * | 2006-03-27 | 2016-12-05 | Univ California | Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES |
US9486524B2 (en) | 2006-09-01 | 2016-11-08 | Genticel | Composition for eliciting a specific CTL response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells |
EP1894941A1 (de) | 2006-09-01 | 2008-03-05 | Institut Pasteur | Behandlung von Gebärmutterhalskarzinomen mit einer rekombinanten Adenylat-Cyclase die HPV-Antigene trägt |
JP6035503B2 (ja) * | 2007-05-31 | 2016-11-30 | アカデミシュ ジーケンハウス ライデン ハー.オー.デー.エン. ルムク | ワクチンで使用するための、子宮頸部悪性腫瘍に浸潤するt細胞によって標的とされるhpvエピトープ |
ES2331271B1 (es) * | 2007-06-29 | 2010-10-14 | Universidad Del Pais Vasco | Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas. |
AU2008280436A1 (en) * | 2007-07-24 | 2009-01-29 | Stichting Katholieke Universiteit Radboud University Nijmegen Medical Centre | Compositions and methods for generating an immune response in a subject |
EP2411513B1 (de) * | 2009-03-23 | 2016-11-09 | Institut Pasteur | Mutierte cyaa-polypeptide und -polypeptidderivate mit eignung zur zuführung immunogener moleküle in eine zelle |
WO2011029980A1 (es) * | 2009-09-11 | 2011-03-17 | Proyecto De Biomedicina Cima, S.L. | Composiciones terapéuticas para el tratamiento de enfermedades causadas por hpv |
CN103119168A (zh) * | 2010-07-15 | 2013-05-22 | 不列颠哥伦比亚癌症局分支机构 | 人乳头瘤病毒e7抗原组合物及其用途 |
EP2478915A1 (de) | 2011-01-24 | 2012-07-25 | Genticel | cyaA-getragene Polypeptid(e) und Verwendung zur Induzierung von therapeutischen und prophylaktischen Immunantworten |
US9308248B2 (en) | 2011-06-17 | 2016-04-12 | Universiteit Gent | Vaccines for Chlamydia |
HUE043361T2 (hu) * | 2011-12-21 | 2019-08-28 | Vaccibody As | HPV elleni vakcinák |
EP2687849A1 (de) * | 2012-07-20 | 2014-01-22 | ISA Pharmaceuticals B.V | Verfahren zur Bereitstellung einer optimierten Immuntherapiezusammensetzung |
EP2690172A1 (de) | 2012-07-23 | 2014-01-29 | Genticel | CYAA-basierte chimäre Proteine mit einem heterologen Polypeptid und deren Verwendungen bei der Induktion von Immunreaktionen |
EP2689786A1 (de) * | 2012-07-23 | 2014-01-29 | Genticel | HPV/CYAA-basierte chimäre Proteine und deren Verwendungen bei der Induktion von Immunreaktionen gegen eine HPV-Infektion und HPV-induzierter Störungen |
US9547006B2 (en) * | 2013-08-08 | 2017-01-17 | Institut Pasteur | Correlation of disease activity with clonal expansions of human papillomavirus 16-specific CD8+ T-cells in patients with severe erosive oral lichen planus |
EP2975120A1 (de) * | 2014-07-17 | 2016-01-20 | Institut Pasteur | Monomeres und funktionelles Adenylatcyclase-CyaA-Toxin |
US10420826B2 (en) | 2014-11-11 | 2019-09-24 | Massachusetts Eye & Ear Infirmary | Conjunctivitis vaccines |
EP3037103A1 (de) | 2014-12-23 | 2016-06-29 | Genticel | Immunotherapeutischer Impfstoff mit E7-Proteinen von HPV16 und HPV18 fusioniert mit CyaA zur Verwendung bei mit HIV infizierten Personen |
DK3271382T3 (da) | 2015-03-16 | 2020-05-04 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Fremgangsmåde til detektion af nye immunogene T-celleepitoper og isolering af nye antigenspecifikke T-cellereceptorer ved hjælp af et MHC-cellebibliotek |
US10736954B2 (en) * | 2016-06-07 | 2020-08-11 | Deutsches Krebsforschungzentrum | L2 peptide immunogenicity |
WO2018091613A1 (en) | 2016-11-17 | 2018-05-24 | Ecole Nationale Vétérinaire de Toulouse | Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection |
EP3323426A1 (de) | 2016-11-17 | 2018-05-23 | Ecole Nationale Vétérinaire de Toulouse | Immunogen- und impfstoffzusammensetzungen zur verwendung gegen bordetella-bronchiseptica-infektion |
EP3342421A1 (de) | 2016-12-27 | 2018-07-04 | Genticel | Immunogene zusammensetzung mit cyaa-abgeleitetem polypeptid, das eine th1/th17-orientierte immunreaktion fördert |
JP7423554B2 (ja) * | 2018-05-30 | 2024-01-29 | ドイチェス クレブスフォルシュンクスツェントルム | 予防用及び治療用の組み合わせワクチン |
WO2021063917A1 (en) | 2019-10-01 | 2021-04-08 | Universiteit Gent | Vaccine against chlamydia in swine |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4015044A1 (de) * | 1990-05-10 | 1991-11-14 | Behringwerke Ag | Seroreaktive epitope auf proteinen des menschlichen papillomavirus (hpv) 18 |
SE9001705D0 (sv) * | 1990-05-11 | 1990-05-11 | Medscand Ab | Saett foer diagnostik av virusbaerande tumoerer genom immunoassay |
US6183745B1 (en) * | 1990-12-12 | 2001-02-06 | The University Of Queensland | Subunit papilloma virus vaccine and peptides for use therein |
DK0637335T3 (da) * | 1992-04-21 | 2007-11-26 | Pasteur Institut | Rekombinante mutanter til induktion af specifikke immunreaktioner |
ES2331348T3 (es) * | 2000-09-15 | 2009-12-30 | Pasteur Institut | Vectores proteinicos para el suministro de moleculas a las celulas que expresan cd11b. |
EP1434859A2 (de) * | 2001-07-25 | 2004-07-07 | New York University | Verwendung von glycosylceramiden als adjuvantien für vakzine gegen infektionen und krebs |
EP1489092A1 (de) | 2003-06-18 | 2004-12-22 | Institut Pasteur | Modifizierte Bordetella Adenylatcyclase mit oder ohne CD11b/CD18 Interaktionsdomäne und seine Verwendungen |
ES2337694T3 (es) * | 2003-11-21 | 2010-04-28 | Institut Pasteur | Toxina de adenilato ciclasa recombinante de bordetella que induce las respuestas de la celula t contra los antigenos tumorales. |
SI1576967T1 (sl) * | 2004-03-18 | 2008-02-29 | Pasteur Institut | Rekombinantni protein, ki nosi epitope humanega papilomavirusa, vstavljene v adenilat ciklazni protein ali njegov fragment, in njegove terapevtske uporabe |
EP1894941A1 (de) * | 2006-09-01 | 2008-03-05 | Institut Pasteur | Behandlung von Gebärmutterhalskarzinomen mit einer rekombinanten Adenylat-Cyclase die HPV-Antigene trägt |
EP2233569B1 (de) | 2009-03-23 | 2014-06-25 | Institut Pasteur | Mutante CyaA-Polypeptide und Polypeptide-Derivate, die zur Lieferung von immunogenen Molekülen in eine Zelle geeignet sind |
-
2004
- 2004-03-18 SI SI200430519T patent/SI1576967T1/sl unknown
- 2004-03-18 PL PL04290741T patent/PL1576967T3/pl unknown
- 2004-03-18 PT PT04290741T patent/PT1576967E/pt unknown
- 2004-03-18 DE DE602004008874T patent/DE602004008874T2/de not_active Expired - Lifetime
- 2004-03-18 EP EP04290741A patent/EP1576967B1/de not_active Expired - Lifetime
- 2004-03-18 DK DK04290741T patent/DK1576967T3/da active
- 2004-03-18 AT AT04290741T patent/ATE372784T1/de active
- 2004-03-18 ES ES04290741T patent/ES2293178T3/es not_active Expired - Lifetime
-
2005
- 2005-03-18 EP EP10181329.3A patent/EP2351580B1/de active Active
- 2005-03-18 KR KR1020137016447A patent/KR101495740B1/ko active IP Right Grant
- 2005-03-18 MX MXPA06010469A patent/MXPA06010469A/es active IP Right Grant
- 2005-03-18 CN CN2005800087095A patent/CN1956730B/zh active Active
- 2005-03-18 RU RU2006131598/10A patent/RU2441022C2/ru active
- 2005-03-18 CA CA2559235A patent/CA2559235C/en active Active
- 2005-03-18 KR KR1020067021582A patent/KR101382250B1/ko active IP Right Grant
- 2005-03-18 BR BRPI0508722-8A patent/BRPI0508722A/pt not_active Application Discontinuation
- 2005-03-18 JP JP2007503308A patent/JP5438897B2/ja active Active
- 2005-03-18 AU AU2005224036A patent/AU2005224036B2/en active Active
- 2005-03-18 WO PCT/EP2005/003452 patent/WO2005089792A1/en active Application Filing
- 2005-03-18 EP EP05728249.3A patent/EP1725259B1/de active Active
-
2006
- 2006-09-08 US US11/517,313 patent/US8628779B2/en active Active
-
2007
- 2007-11-29 CY CY20071101529T patent/CY1107042T1/el unknown
-
2010
- 2010-12-23 US US12/977,754 patent/US8637039B2/en active Active
-
2013
- 2013-05-21 JP JP2013107236A patent/JP5824474B2/ja not_active Expired - Fee Related
- 2013-12-16 US US14/106,921 patent/US9387243B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE372784T1 (de) | Rekombinante proteine, die epitope des humanen papillomavirus inseriert in einem adenylatecyclase protein oder in dessen fragmenten tragen, und deren terapeutischen verwendung. | |
WO2008026071A3 (en) | Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying hpv antigens | |
MX2010002716A (es) | Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago. | |
MX2009013824A (es) | Proteinas de enlace de antigeno que enlazan par-2. | |
PL367831A1 (en) | Recombinant tumor specific antibody and use thereof | |
DE602006021296D1 (de) | Monoklonale antikörper und einzelkettenantikörper fragments gegen das zelloberflächen prostataspezifische membranantigen | |
GEP20105059B (en) | Anti-cd154 antibodies | |
SI1572087T1 (sl) | Protitelesa proti antigenu tmeff2 raka in njihovauporaba | |
BRPI0606790A2 (pt) | anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna. | |
WO2006060680A3 (en) | Mda-7 protein variants having antiproliferative activity | |
UA107330C2 (uk) | Туберкульозний білок rv3616c та його застосування | |
MX2022000325A (es) | Anticuerpos dirigidos contra dll3 y usos de los mismos. | |
GEP20105022B (en) | Use of polypeptides of the cupredoxin family in cancer therapy | |
MX2008008185A (es) | Antigenos de acido des-n-acetil-sialico, anticuerpos para los mismos, y metodos de uso en la terapia de cancer. | |
MX2018013081A (es) | Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia. | |
WO2006031363A3 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
TW200716161A (en) | Compositions and methods for treating or preventing overweight or obesity with zinc-charged protein fragments | |
WO2021181233A3 (en) | Cd80-fc fusion protein and uses thereof | |
MX2007003624A (es) | Peptidos y derivados tipo peptido ligando alterado de la hsp60 y composiciones farmaceuticas. | |
MX2020008403A (es) | Receptores de celulas t especificos de ciclina a1 y usos de los mismos. | |
RS20050577A (en) | Compositions and methods for treating cancer using igsf9 and liv-1 | |
WO2004094476A3 (en) | Compositions and methods relating to stop-1 | |
EP2193804A3 (de) | Rekombinantes Adenylat-Cyclase-Toxin von Bordetella induziert T-Zell-Antworten gegen tumorale Antigene | |
MX2021008453A (es) | Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos. | |
MX2021013426A (es) | Tratamiento de la cefalea usando anticuerpos anti-cgrp. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR Owner name: INSTITUT PASTEUR, PARIS, FR Owner name: GENTICEL, LABEGE, FR Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (, FR |